SCHEMBL1707753

SCHEMBL1707753

COC(=O)c1cccc(Nc2ccccc2N)c1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
HSD17B10 Q99714 2/20 0.60
CFTR P13569 1/20 0.60
CDC25B P30305 3/20 0.51
KDM4E B2RXH2 3/20 0.50
MAPT P10636 2/20 0.50
NPC1 O15118 2/20 0.50
POLB P06746 1/20 0.50
ATM Q13315 1/20 0.50
ALOX15 P16050 1/20 0.50
FFAR4 Q5NUL3 1/20 0.50
CASP3 P42574 1/20 0.50
RAB9A P51151 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
MAPK13 O15264 3/20 0.49
MAPK12 P53778 3/20 0.49
MAPK11 Q15759 3/20 0.49
MAPK14 Q16539 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2314122 0.87 HSD17B10 (0.68) ALDH1A1HSD17B10CFTRCDC25BKDM4E
SCHEMBL1708210 0.86 FFAR4 (0.52) ALDH1A1HSD17B10CFTRCDC25BKDM4E
SCHEMBL1707792 0.84 ALDH1A1 (0.51) ALDH1A1HSD17B10CFTRCDC25BKDM4E
SCHEMBL1707815 0.84 ALDH1A1 (0.44) ALDH1A1HSD17B10CFTRKDM4EMAPT
SCHEMBL1707810 0.84 LMNA (0.54) ALDH1A1HSD17B10CFTRKDM4ENPC1
SCHEMBL1707847 0.84 LMNA (0.54) ALDH1A1HSD17B10CFTRCDC25BKDM4E
SCHEMBL1708579 0.84 ALDH1A1 (0.44) ALDH1A1HSD17B10CFTRCDC25BKDM4E
SCHEMBL1707741 0.84 LMNA (0.50) ALDH1A1HSD17B10CFTRKDM4EMAPT
SCHEMBL543352 0.82 ALDH1A1 (0.69) ALDH1A1HSD17B10CFTRKDM4EMAPT
SCHEMBL31303445 0.82 ALDH1A1 (0.69) ALDH1A1HSD17B10CFTRKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120172351-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 US disclosed
EP-2440541-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-04-18 EP disclosed
WO-2010143733-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172351-A1 NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF GPR119, INSR, GLP1R ALDH1A1 3930/4885HSD17B10 774/4885CFTR 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.